Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP and CMO | June 26, 2026 | June 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
VERTEX PHARMACEUTICALS INC / MA
Report date June 26, 2026 · Filed June 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,337 |
Reported balance
After 2026-06-26 transaction · row 1
1 source rowRow 1 · 2026-06-26 · Sale · Disposed 596 · Balance 15,337 F1: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 30, 2026 20:09 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 596 | $482.50 | $287,570.00 |
DisclosureSEC source: 0000875320-26-000239 · wk-form4_1782850180.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,337 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 20:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,020 | $462.17 | $471,413.40 |
DisclosureSEC source: 0000875320-26-000237 · wk-form4_1782245334.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,933 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| June 15, 2026 Filed Jun 17, 2026 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 4,062 | $450.00 | $1,827,900.00 |
DisclosureSEC source: 0000875320-26-000235 · wk-form4_1781727153.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,953 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 20:24 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,745 | $450.00 | $785,250.00 |
DisclosureSEC source: 0000875320-26-000233 · wk-form4_1781036661.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 21,015 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| May 29, 2026 Filed Jun 2, 2026 20:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,974 | $450.00 | $888,300.00 |
DisclosureSEC source: 0000875320-26-000228 · wk-form4_1780430661.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,760 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| May 15, 2026 Filed May 19, 2026 20:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,354 | $453.45 | $613,971.30 |
DisclosureSEC source: 0000875320-26-000225 · wk-form4_1779221059.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,734 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| May 12, 2026 Filed May 14, 2026 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 6,988 | $450.00 | $3,144,600.00 |
DisclosureSEC source: 0000875320-26-000222 · wk-form4_1778789402.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 26,088 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| March 27, 2026 Filed Mar 31, 2026 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,329 | $450.95 | $1,050,262.55 |
DisclosureSEC source: 0000875320-26-000149 · wk-form4_1774987818.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 33,076 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| March 13, 2026 Filed Mar 17, 2026 20:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,329 | $481.79 | $1,122,088.91 |
DisclosureSEC source: 0000875320-26-000140 · wk-form4_1773777858.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 35,405 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| February 27, 2026 Filed Mar 3, 2026 21:25 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,329 | $480.31 | $1,118,641.99 |
DisclosureSEC source: 0000875320-26-000127 · wk-form4_1772573117.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 37,734 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 11/20/2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:05 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,453 | $485.11 | $704,864.83 |
DisclosureSEC source: 0000875320-26-000110 · wk-form4_1772147118.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,063 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,912 | $483.75 | $924,930.00 |
DisclosureSEC source: 0000875320-26-000086 · wk-form4_1771535456.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,516 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,375 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000086 · wk-form4_1771535456.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,428 F1 · shares: Restricted stock unit award that vests in installments beginning on February 20, 2027. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,804 | $487.76 | $1,855,439.04 |
DisclosureSEC source: 0000875320-26-000066 · wk-form4_1771450120.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,053 Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:53 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,145 | $468.41 | $1,004,739.45 |
DisclosureSEC source: 0000875320-26-000042 · wk-form4_1770933202.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,857 Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 3,467 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000016 · wk-form4_1769462535.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,002 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:22 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000016 · wk-form4_1769462535.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,535 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Read SEC document |
| February 26, 2025 Filed Feb 28, 2025 21:41 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 4,962 | $479.61 | $2,379,824.82 |
DisclosureSEC source: 0000875320-25-000129 · wk-form4_1740778869.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,669 Read SEC document |
| February 24, 2025 Filed Feb 26, 2025 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,310 | $483.28 | $1,599,656.80 |
DisclosureSEC source: 0000875320-25-000109 · wk-form4_1740604253.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,631 Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,912 | $463.46 | $886,135.52 |
DisclosureSEC source: 0000875320-25-000087 · wk-form4_1740000615.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,941 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,546 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000065 · wk-form4_1739567507.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,853 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026. Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:38 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,142 | $467.98 | $1,002,413.16 |
DisclosureSEC source: 0000875320-25-000041 · wk-form4_1739396310.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,307 Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000016 · wk-form4_1738877728.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,449 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025. Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:35 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,262 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000016 · wk-form4_1738877728.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,521 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest on 02/26/2025. Read SEC document |
| August 07, 2024 Filed Aug 8, 2024 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,280 | $476.75 | $1,086,990.00 |
DisclosureSEC source: 0000875320-24-000202 · wk-form4_1723147577.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 23,259 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2024. Read SEC document |
| July 24, 2024 Filed Jul 25, 2024 20:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,280 | $488.46 | $1,113,688.80 |
DisclosureSEC source: 0000875320-24-000189 · wk-form4_1721937956.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 25,539 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2024. Read SEC document |
| July 10, 2024 Filed Jul 12, 2024 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,280 | $487.34 | $1,111,135.20 |
DisclosureSEC source: 0000875320-24-000183 · wk-form4_1720814825.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 27,819 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2024. Read SEC document |
| June 26, 2024 Filed Jun 28, 2024 20:04 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,280 | $471.72 | $1,075,521.60 |
DisclosureSEC source: 0000875320-24-000181 · wk-form4_1719605071.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 30,099 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2024. Read SEC document |
| June 12, 2024 Filed Jun 13, 2024 20:11 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,280 | $478.00 | $1,089,840.00 |
DisclosureSEC source: 0000875320-24-000176 · wk-form4_1718309487.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 32,379 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2024. Read SEC document |
| May 29, 2024 Filed May 31, 2024 20:19 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,280 | $445.56 | $1,015,876.80 |
DisclosureSEC source: 0000875320-24-000164 · wk-form4_1717186773.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,659 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2024. Read SEC document |
| February 23, 2024 Filed Feb 27, 2024 21:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,309 | $431.79 | $1,428,793.11 |
DisclosureSEC source: 0000875320-24-000103 · wk-form4_1709070601.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,939 Read SEC document |
| February 20, 2024 Filed Feb 21, 2024 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,812 | $420.58 | $1,182,670.96 |
DisclosureSEC source: 0000875320-24-000072 · wk-form4_1708550788.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,248 Read SEC document |
| February 16, 2024 Filed Feb 21, 2024 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,750 | $424.01 | $1,590,037.50 |
DisclosureSEC source: 0000875320-24-000072 · wk-form4_1708550788.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,060 Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 22:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,100 | $422.74 | $887,754.00 |
DisclosureSEC source: 0000875320-24-000049 · wk-form4_1707861651.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,810 Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,928 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000024 · wk-form4_1707427972.xml · nonDerivative · entry 3 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,910 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2025. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000024 · wk-form4_1707427972.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 42,982 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:33 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,814 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000024 · wk-form4_1707427972.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,116 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest on 02/20/2024. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 21:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,650 | $380.82 | $2,151,633.00 |
DisclosureSEC source: 0000875320-23-000037 · wk-form4_1700169311.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,302 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023. Read SEC document |
| October 31, 2023 Filed Nov 2, 2023 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,651 | $355.92 | $2,011,303.92 |
DisclosureSEC source: 0000875320-23-000025 · wk-form4_1698955627.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,952 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023. Read SEC document |
| October 17, 2023 Filed Oct 19, 2023 20:18 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,651 | $373.25 | $2,109,235.75 |
DisclosureSEC source: 0001209191-23-053178 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,603 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023. Read SEC document |
| October 03, 2023 Filed Oct 5, 2023 20:30 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,651 | $345.28 | $1,951,177.28 |
DisclosureSEC source: 0001209191-23-052202 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,254 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023. Read SEC document |
| September 19, 2023 Filed Sep 21, 2023 20:15 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,651 | $351.00 | $1,983,501.00 |
DisclosureSEC source: 0001209191-23-050259 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,905 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023. Read SEC document |
| September 05, 2023 Filed Sep 7, 2023 20:29 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 5,651 | $352.66 | $1,992,881.66 |
DisclosureSEC source: 0001209191-23-048624 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 57,556 F1 · kind: Transaction made pursuant to Dr. Bozic's company approved trading plan under Rule 10b5-1, which was entered into on 05/30/2023. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 21:50 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,308 | $289.12 | $956,408.96 |
DisclosureSEC source: 0001209191-23-013713 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,207 Read SEC document |
| February 17, 2023 Filed Feb 22, 2023 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 3,750 | $292.85 | $1,098,187.50 |
DisclosureSEC source: 0001209191-23-011680 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,515 Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 21:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 4,992 | $298.26 | $1,488,913.92 |
DisclosureSEC source: 0001209191-23-009190 · doc4.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,265 Read SEC document |
| February 10, 2023 Filed Feb 14, 2023 21:55 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,707 | $294.33 | $796,751.31 |
DisclosureSEC source: 0001209191-23-009190 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,257 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 7,866 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006934 · doc4.xml · nonDerivative · entry 3 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,964 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,262 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006934 · doc4.xml · nonDerivative · entry 2 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,098 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2022 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest in installments beginning on 02/24/2023. Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:44 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 10,324 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006934 · doc4.xml · nonDerivative · entry 1 Bozic Carmen · CIK 0001790029 · EVP and CMO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,836 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/05/2020 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2023 and the shares will vest on 02/13/2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.